41 – 50 of 62
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
(
- Contribution to journal › Article
-
Mark
Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
(
- Contribution to journal › Article
-
Mark
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
(
- Contribution to journal › Article
- 2007
-
Mark
Serum calcium is an independent predictor of quality of life in multiple myeloma
(
- Contribution to journal › Article
-
Mark
Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults.
(
- Contribution to journal › Article
- 2006
-
Mark
Quality assessment of autografting by probability evaluation: model estimation by clinical end-points in newly diagnosed multiple myeloma patients
(
- Contribution to journal › Article
-
Mark
Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells
(
- Contribution to journal › Article
-
Mark
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
(
- Contribution to journal › Article